Mariëlle S Klein Hesselink1, Marloes Nies1, Gianni Bocca1, Adrienne H Brouwers1, Johannes G M Burgerhof1, Eveline W C M van Dam1, Bas Havekes1, Marry M van den Heuvel-Eibrink1, Eleonora P M Corssmit1, Leontien C M Kremer1, Romana T Netea-Maier1, Heleen J H van der Pal1, Robin P Peeters1, Kurt W Schmid1, Johannes W A Smit1, Graham R Williams1, John T M Plukker1, Cécile M Ronckers1, Hanneke M van Santen1, Wim J E Tissing1, Thera P Links1. 1. Departments of Endocrinology (M.S.K.H., M.N., T.P.L.), Nuclear Medicine and Molecular Imaging (A.H.B.), Epidemiology (J.G.M.B.), and Surgical Oncology (J.T.M.P.), University of Groningen, University Medical Center Groningen, and Departments of Pediatric Endocrinology (G.B.) and Pediatric Oncology (W.J.E.T.), Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands; Department of Internal Medicine (E.W.C.M.v.D.), VU University Medical Center, 1007 MB Amsterdam, The Netherlands; Department of Internal Medicine (B.H.), Division of Endocrinology, Maastricht University Medical Center, 6202 AZ Maastricht, The Netherlands; Department of Pediatric Oncology (M.M.v.d.H.-E.), Sophia Children's Hospital, Erasmus Medical Center, 3000 CB Rotterdam, The Netherlands; Department of Internal Medicine (E.P.M.C.), Division of Endocrinology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Department of Pediatric Oncology (L.C.M.K., H.J.H.v.d.P., C.M.R.), Emma Children's Hospital, Academic Medical Center, 1100 DD Amsterdam, The Netherlands; Department of Internal Medicine (R.T.N.-M., J.W.A.S.), Division of Endocrinology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands; Department of Medical Oncology (H.J.H.v.d.P.), Academic Medical Center, 1100 DD Amsterdam, The Netherlands; Department of Internal Medicine (R.P.P.) and Rotterdam Thyroid Center (R.P.P.), Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands; Institute of Pathology (K.W.S.), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany; Department of Medicine (G.R.W.), Imperial College London, London SW7 2AZ, United Kingdom; and Department of Pediatrics (H.M.v.S.), Wilhelmina Children's Hospital, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
Abstract
INTRODUCTION: Treatment for differentiated thyroid carcinoma (DTC) in pediatric patients is based mainly on evidence from adult series due to lack of data from pediatric cohorts. Our objective was to evaluate presentation, treatment-related complications, and long-term outcome in patients with pediatric DTC in The Netherlands. PATIENTS AND METHODS: In this nationwide study, presentation, complications, and outcome of patients with pediatric DTC (age at diagnosis ≤18 y) treated in The Netherlands between 1970 and 2013 were assessed using medical records. RESULTS: We identified 170 patients. Overall survival was 99.4% after a median follow-up of 13.5 years (range 0.3-44.7 y). Extensive follow-up data were available for 105 patients (83.8% women), treated in 39 hospitals. Median age at diagnosis was 15.6 years (range 5.8-18.9 y). At initial diagnosis, 43.8% of the patients had cervical lymph node metastases; 13.3% had distant metastases. All patients underwent total thyroidectomy. Radioiodine was administered to 97.1%, with a median cumulative activity of 5.66 GBq (range 0.74-35.15 GBq). Life-long postoperative complications (permanent hypoparathyroidism and/or recurrent laryngeal nerve injury) were present in 32.4% of the patients. At last known follow-up, 8.6% of the patients had persistent disease and 7.6% experienced a recurrence. TSH suppression was not associated with recurrences (odds ratio 2.00, 95% confidence interval 0.78-5.17, P = .152). CONCLUSIONS: Survival of pediatric DTC is excellent. Therefore, minimizing treatment-related morbidity takes major priority. Our study shows a frequent occurrence of life-long postoperative complications. Adverse effects may be reduced by the centralization of care, which is crucial for children with DTC.
INTRODUCTION: Treatment for differentiated thyroid carcinoma (DTC) in pediatric patients is based mainly on evidence from adult series due to lack of data from pediatric cohorts. Our objective was to evaluate presentation, treatment-related complications, and long-term outcome in patients with pediatric DTC in The Netherlands. PATIENTS AND METHODS: In this nationwide study, presentation, complications, and outcome of patients with pediatric DTC (age at diagnosis ≤18 y) treated in The Netherlands between 1970 and 2013 were assessed using medical records. RESULTS: We identified 170 patients. Overall survival was 99.4% after a median follow-up of 13.5 years (range 0.3-44.7 y). Extensive follow-up data were available for 105 patients (83.8% women), treated in 39 hospitals. Median age at diagnosis was 15.6 years (range 5.8-18.9 y). At initial diagnosis, 43.8% of the patients had cervical lymph node metastases; 13.3% had distant metastases. All patients underwent total thyroidectomy. Radioiodine was administered to 97.1%, with a median cumulative activity of 5.66 GBq (range 0.74-35.15 GBq). Life-long postoperative complications (permanent hypoparathyroidism and/or recurrent laryngeal nerve injury) were present in 32.4% of the patients. At last known follow-up, 8.6% of the patients had persistent disease and 7.6% experienced a recurrence. TSH suppression was not associated with recurrences (odds ratio 2.00, 95% confidence interval 0.78-5.17, P = .152). CONCLUSIONS: Survival of pediatric DTC is excellent. Therefore, minimizing treatment-related morbidity takes major priority. Our study shows a frequent occurrence of life-long postoperative complications. Adverse effects may be reduced by the centralization of care, which is crucial for children with DTC.
Authors: Seo Young Sohn; Young Nam Kim; Hye In Kim; Tae Hyuk Kim; Sun Wook Kim; Jae Hoon Chung Journal: Endocrine Date: 2017-08-18 Impact factor: 3.633
Authors: Marwan H Adly; Mohamed Sobhy; Mohamed A Rezk; Medhat Ishak; Mahmoud A Afifi; Ayman El Shafie; Mahmoud Ahmed Ali; Wael Zekri; Ahmad Samir Alfaar; Wafaa M Rashed Journal: Int J Clin Oncol Date: 2018-02-28 Impact factor: 3.402
Authors: Joke Van Vlaenderen; Karl Logghe; Eva Schiettecatte; Hubert Vermeersch; Wouter Huvenne; Kathleen De Waele; Hanne Van Beveren; Jo Van Dorpe; David Creytens; Jean De Schepper Journal: Int J Pediatr Endocrinol Date: 2020-07-21
Authors: Marloes Nies; Bernadette L Dekker; Esther Sulkers; Gea A Huizinga; Mariëlle S Klein Hesselink; Heleen Maurice-Stam; Martha A Grootenhuis; Adrienne H Brouwers; Johannes G M Burgerhof; Eveline W C M van Dam; Bas Havekes; Marry M van den Heuvel-Eibrink; Eleonora P M Corssmit; Leontien C M Kremer; Romana T Netea-Maier; Heleen J H van der Pal; Robin P Peeters; John T M Plukker; Cécile M Ronckers; Hanneke M van Santen; Anouk N A van der Horst-Schrivers; Wim J E Tissing; Gianni Bocca; Thera P Links Journal: Eur J Endocrinol Date: 2017-12-18 Impact factor: 6.664
Authors: Marloes Nies; Rena Vassilopoulou-Sellin; Roland L Bassett; Sireesha Yedururi; Mark E Zafereo; Maria E Cabanillas; Steven I Sherman; Thera P Links; Steven G Waguespack Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 5.958